SBCIndustrials · Consulting Services

SBC Stock Forecast: SBC Medical Group Holdings, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026

$4.75

+1.28% on the day

The 3 Wall Street analysts covering SBC Medical Group Holdings, Inc. hold a median 12-month price target of $8.5 — +78.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 19 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap

$488.5M

Ticker Nerd rank

73 / 100

Median analyst target

$8.50

Analysts covering

Revenue$49.2M+13.4% y/y

Operating income$19.0M

Net income$11.2M

Free cash flow$22.0M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+6.5%

+31.9%

YTD

+10.2%

+2.2%

From 52W high

−3.5%

From 52W low

+65.5%

$2.87

$4.92

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

SBC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SBC Medical Group Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026

73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value

Volatility

Quality

Revisions

Momentum

Accruals

Size

Growth

Issuance

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SBC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SBC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts

3 Buy0 Hold0 Sell

Low $7.00Median $8.50High $11.00

The green dot is the last close — the median target sits +78.9% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
13 Aug 2026	BTIG	Reiterates	Buy	$8.00
6 Mar 2026	BTIG	Initiates	Buy	—
6 Mar 2026	BTIG	Initiates	Buy	$8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SBC appears on the weeks it earns a place.

Performance

SBC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, SBC Medical Group Holdings, Inc. returned +2.2% against +16.3% for the S&P 500, dividends included.

SBC vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SBC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

EPS revision, 90 days

−1.1%

Analysts raising

Analysts cutting

Fundamentals

SBC Medical Group Holdings, Inc. (SBC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 9.9×
Price / sales: 2.8×
Price / book: 1.8×
EV / EBITDA: 5.4×

Growth & margins

Revenue growth (YoY): 13.4%
Earnings growth (YoY): 335.0%
Gross margin: 73.1%
Operating margin: 38.5%
Net margin: 28.0%

Returns & dividend

Return on equity: 18.9%
Return on assets: 11.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SBC Medical Group Holdings, Inc. (SBC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

SBC Medical Group Holdings, Inc. has a market value of $488.5M and an enterprise value of $368.2M.
Revenue in the twelve months to 30 June 2026: $175.2M. The latest quarter grew 13.4% year on year.
Net income over the same four quarters: $49.6M, a 28.3% net margin.
Diluted earnings per share, trailing twelve months: $0.47.
Free cash flow in the twelve months to 30 June 2026: $60.4M.
Shares outstanding: 102.6M.
Trailing P/E: 9.9×; forward P/E: 8.8× — the forward figure prices analyst consensus estimates, not reported earnings.
SBC Medical Group Holdings, Inc. employs 863 people — $203K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

SBC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelConsulting Services

Company	Market cap	TKN rank
SBCSBC Medical Group Holdings, Inc.	$488.5M	73
ROMARoma Green Finance Ltd.	$558.1M	19
PPHCPublic Policy Holding Co., Inc.	$396.1M	35
CRAICRA International, Inc.	$1.1B	45
FORRForrester Research, Inc.	$210.9M	80
ICFIICF International, Inc.	$1.6B	81
RGPResources Connection, Inc.	$132.2M	53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SBC Medical Group Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SBC news & analysis

SBC Medical to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Newsfile Corp · 10 Sept 2026neutral

SBC Medical Group Holdings announced it will participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026, at the Sheraton Center Toronto Hotel. Hikaru Fukui, Head of the IR department, will present on the company's recent milestones and future growth strategy.

Why it matters — The presentation offers SBC watchers an opportunity to hear directly from the company's IR head about its recent progress and forward-looking plans at a growth-focused investor summit.

SBC Medical to Participate in Several Upcoming Investor Conferences in September 2026

Business Wire · 1 Sept 2026neutral

SBC Medical announced it will conduct a Non-Deal Roadshow and participate in several investor conferences throughout September 2026. The company noted these planned engagements as part of its investor-relations activities.

Why it matters — Investors following SBC may see the company's scheduled presentations at these conferences as opportunities for increased visibility and engagement with the investing community.

SBC Medical Group Re-Accelerates Growth as EBITDA Surges 32% in Q2

MarketBeat · 30 Aug 2026positive

SBC Medical Group reported that its growth re-accelerated in the second quarter of 2026 following structural reforms made in 2025, with profit growth outpacing revenue growth as management services revenue expanded and service fees increased.

Why it matters — The re-acceleration of growth and profit growth exceeding revenue growth indicate that the company's 2025 structural reforms are yielding results for SBC watchers.

Emerging Growth Research Issues Updated Press Release Announcing Company-Sponsored Research on SBC Medical Group Holdings Incorporated

Accesswire · 27 Aug 2026neutral

Emerging Growth Research, LLC announced the release of an updated version of its press release regarding its company-sponsored quarterly research update (Q2:26) on SBC Medical Group Holdings Incorporated, which provides management services to cosmetic treatment centers via a franchise model across Japan, Vietnam, Thailand, Singapore, and the United States.

Why it matters — SBC watchers would be alerted to the release of fresh company-sponsored research coverage on SBC, potentially offering updated analysis of the company's operations and franchise business across multiple markets.

Emerging Growth Research Releases Q2:26 Quarterly Update on SBC Medical Group; Reiterates Buy Rating and Increases Price Target to $11.00

Accesswire · 24 Aug 2026positive

Emerging Growth Research released its Q2:26 Quarterly Update Report on SBC Medical Group, reiterating a Buy rating and raising its 12-month price target to $11.00 from $10.00. The report highlights SBC's return to revenue growth in 2026 following 2025 pricing-related headwinds, citing a strong cash position, expanding clinic footprint, continued international expansion, and new AI-driven growth initiatives.

Why it matters — An analyst research firm has reaffirmed a favorable view of SBC and raised its price target, while pointing to renewed revenue growth and several expansion levers that SBC watchers would closely track.

FAQ

Frequently asked questions about SBC stock

What is the SBC stock price forecast for 2026-2027?

The 3 Wall Street analysts covering SBC Medical Group Holdings, Inc. have a median 12-month price target of $8.5, with estimates ranging from $7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SBC stock a buy right now?

Of the 3 analysts covering SBC Medical Group Holdings, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SBC Medical Group Holdings, Inc. 73 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SBC?

As at 19 Sept 2026, SBC Medical Group Holdings, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will SBC stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +78.9% from the last close, and Ticker Nerd's factor model ranks SBC Medical Group Holdings, Inc. 73 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SBC stock forecast for 2030?

No analyst covering SBC Medical Group Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SBC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $11 over the next 12 months.

How has SBC stock performed over the past year?

SBC Medical Group Holdings, Inc. returned +2.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SBC Medical Group Holdings, Inc. do?

SBC Medical Group Holdings Inc. is a medical services organization that provides management support and related products to cosmetic treatment centers and broader medical institutions.

What is the latest news on SBC?

The most recent item we track (Newsfile Corp, 10 Sept 2026): "SBC Medical to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto". SBC Medical Group Holdings announced it will participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026, at the Sheraton Center Toronto Hotel. Hikaru Fukui, Head of the IR department, will present on the company's recent milestones and future growth strategy.

Company

About SBC Medical Group Holdings, Inc.

SBC Medical Group Holdings Inc. is a medical services organization that provides management support and related products to cosmetic treatment centers and broader medical institutions. Its core activities include clinic operations support, marketing, staffing, reservation management, facility coordination, construction and design assistance, procurement of medical equipment and consumables, and the licensing of medical technologies, trademarks, and brand use. The company also offers digital tools such as IT software solutions and remote consultation support, helping clinics improve day-to-day administration and patient services. SBC Medical Group Holdings Inc. operates through a network of clinics and franchisee partners across Japan and selected international markets, with services spanning aesthetic medicine, dermatology, dentistry, hair loss treatment, fertility care, ophthalmology, orthopedics, and regenerative medicine.

CEO Dr. Yoshiyuki Aikawa · 863 employees · United States · https://sbc-holdings.com